TOLERABILITY OF VARIOUS ANTIHYPERTENSIVE COMBINATIONS
https://doi.org/10.20996/1819-6446-2009-5-4-21-24
Abstract
Aim. To compare tolerability of various antihypertensive combinations in patients with arterial hypertension (HT).
Material and methods. 140 patients with HT with history of non-effective antihypertensive therapy were randomized in 4 groups, 35 patients in each. Patients of group A received indapamide retard/perindopril; group B - indapamide retard/amlodipine; group C – amlodipine/lisinopril; group D – amlodipine/bisoprolol. Therapy duration was 12 weeks.
Results. 28 (20%) patients dropped out of the study. All antihypertensive combinations significantly decreased blood pressure level. Patients of group A did not stop therapy because of adverse events. 6 (17,1%) dropped out of the study because of ineffective therapy in maximal doses and therapy rejection. Palpitation was a reason of drug withdrawal in 3 (8,6%) of 8 (22,9%) dropped patients of group B. Low limb edema was a reason of drug withdrawal in 4 (11,4%) of 8 (22,9%) dropped patients of group D. Cough was a reason of drug withdrawal in 4 (11,4%) of 5 dropped patients of group C. Dose reduction was needed in some patients of all groups because of hypotension.
Conclusion. The adverse events were observed in 25% of patients during 12 weeks of therapy. The patients received indapamide retard/amlodipine and amlodipine/bisoprolol had the highest rate of drug withdrawal because of adverse events. Low limb edema, cough and palpitation were the most frequent adverse events needed therapy withdrawal.
About the Authors
S. V. Malchikova
Kirov State Medical Academy
Russian Federation
K. Marxa ul. 112, Kirov, 610027
Russian Federation
K. Marxa ul. 112, Kirov, 610027
E. I. Tarlovskaya
Kirov State Medical Academy
Russian Federation
K. Marxa ul. 112, Kirov, 610027
Russian Federation
K. Marxa ul. 112, Kirov, 610027
References
1. Кукес В.Г., Морозов П.Н., редакторы. Нежелательные эффекты лекарственных средств. М.: Русский врач; 2006.
2. Ross S.D., Akhras K.S., Zhang S. et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001;21(8):940-53.
3. Mancia G., Backer G., Dominiczak A. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25(6):1105- 87.
4. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипетронии. Кардиоваскулярная терапия и профилактика 2008; 7(6 приложение 2):3-32.
5. Стуров Н.В. Использование фиксированной комбинации фозиноприла с гидрохлортиазидом при лечении артериальной гипертонии. Трудный пациент 2007;(8):9-11.
6. Леонова М.В, Манешина О.А. Комплекс квинаприл и гидрохлортиазид - новый фиксированный комбинированный препарат для лечения артериальной гипертонии. Consilium Medicum 2007;2(1):3-7.
7. Neldam S., Edwards C.; ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006;15(3):151-60.
8. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290(21):2805–16.
9. Проект Рекомендаций экспертов ВНОК по диагностике и лечению метаболического синдрома (второй пересмотр). М.: ВНОК; 2009. 10. Корзун А.И., Кириллова М.В. Сравнительная характеристика ингибиторов АПФ. Экология человека 2003;(2):16-22.
Review
For citations:
Malchikova S.V., Tarlovskaya E.I. TOLERABILITY OF VARIOUS ANTIHYPERTENSIVE COMBINATIONS. Rational Pharmacotherapy in Cardiology. 2009;5(4):21-24. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-4-21-24
Views: 1587
Email this article 